Serum osteoprotegerin: Bone or cardiovascular marker in Type 2 diabetes males?

Background: The role of osteoprotegerin (OPG) as a marker of cardiovascular disease (CVD) in Type 2 diabetes (T2DM) is not well established. Moreover, the relationship between OPG, osteoporosis, and vertebral fractures in T2DM remains to be elucidated. Aim: To determine the role of serum OPG in the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of endocrinological investigation 2013, Vol.36 (1), p.16-20
Main Authors: Moreno, P. Rozas, García, R. Reyes, García-Martín, A., Varsavsky, M., García-Salcedo, J. A., Muñoz-Torres, M.
Format: Article
Language:English
Subjects:
Absorptiometry, Photon
Biomarkers - blood
Blood Pressure Determination
Bone Density
Bone Diseases - blood
Bone Diseases - diagnosis
Bone Diseases - etiology
Cardiovascular Diseases - blood
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - etiology
Carotid Intima-Media Thickness
Cross-Sectional Studies
Diabetes Complications - blood
Diabetes Complications - diagnosis
Diabetes Complications - etiology
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - physiopathology
Endocrinology
Female
Humans
Male
Medicine
Medicine & Public Health
Metabolic Diseases
Middle Aged
Original Articles
Osteoprotegerin - blood
Prognosis
Risk Factors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The role of osteoprotegerin (OPG) as a marker of cardiovascular disease (CVD) in Type 2 diabetes (T2DM) is not well established. Moreover, the relationship between OPG, osteoporosis, and vertebral fractures in T2DM remains to be elucidated. Aim: To determine the role of serum OPG in the prediction of CVD and bone disease in T2DM males. Subjects and methods: Cross-sectional study with 68 males, 43 with T2DM and 25 subjects without diabetes. We measured: serum OPG by inmunoassay, the presence of CVD (coronary heart disease, cerebrovascular and peripheral artery disease), surrogate markers of CVD [intima-media thickness (IMT) and aortic calcification] and bone disease (bone mineral density and prevalent vertebral fractures). Results: OPG serum levels (in pmol/l) were significantly higher in T2DM males with abnormal IMT (5. 12±1. 59 vs 3. 76±1. 98), carotid plaque (5. 46±1. 67 vs 4. 20±1. 81), aortic calcification (5. 91±1. 39 vs 4. 07±1. 76), hypertension (5. 11 ±1. 86 vs 3. 81 ±1. 47), and peripheral artery disease (6. 24±1. 64 vs 4. 21 ±1. 63, p
ISSN:0391-4097
1720-8386
DOI:10.3275/8285